2026年5月27日，《福布斯》正式发布2026年全球最佳创投人榜（The Midas List）。启明创投主管合伙人周志峰作为来自中国的科技特别是AI投资人首次上榜，位列第80位。

Midas List被誉为“投资界奥斯卡”，是全球创业投资行业最具影响力的投资人榜单。今年适逢榜单创立25周年，竞争尤为激烈——SpaceX、OpenAI和Anthropic的估值飙升带动了25位新投资人上榜。

周志峰于2014年加入启明创投，2024年5月晋升为主管合伙人。周志峰拥有超过20年的产业、创业与投资复合经验，长期专注于前沿科技领域，是人工智能、机器人等变革性技术领域最活跃的投资人之一。

进入2026年以来，仅5个月内，周志峰所投资的企业中，就有壁仞科技、智谱、爱芯元智、云英谷科技4家企业接连登陆资本市场。

在科技特别是AI投资领域，周志峰始终坚持“快半步”的方法论——在自己建立了“能力圈”的一些领域，敏锐捕捉产业关键信号，预判趋势并提前布局，而不是在市场热潮来临时跟风入场。他认为，面对范式转移级别的浪潮，这是取得超额回报的最优投资方法。

2019年底，国内GPU赛道参与者寥寥、AI 算力需求未被主流认知时，周志峰以创始投资人身份在壁仞科技成立之际就前瞻性入局，领投其首轮融资并持续加码，一路支持其成长为港股GPU第一股。

2022年初，人工智能发展前景尚不明朗，市场还没有提出大模型的概念，甚至鲜有投资人观察到技术变革的信号，周志峰便投资了智谱。那一轮资金支持智谱研发了GLM初代模型。

在具身智能领域，除了在11年前布局优必选机器人，周志峰带领团队在近年新一轮发展的早期阶段就投资了它石智航、原力灵机、银河通用、大晓机器人等模型与本体一体化的全栈公司。

启明创投成立于2006年，如今管理11只美元基金和7只人民币基金，资产管理规模达95亿美元。自成立以来，启明创投始终专注于两大核心板块：科技与医疗创新，形成了独特的“双轮驱动”格局。

在科技领域，启明创投已深耕AI领域十余年——自2013年起布局深度学习，累计投资超100个AI项目，投资总额达120亿元人民币，投资企业覆盖AI产业全链条，是人工智能领域中国乃至亚洲最活跃、最具影响力的投资机构之一。从大模型到多模态，再到具身智能，启明创投的投资决策始终以科技发展曲线为主线，而非盲目追逐资本市场的短期热点。

在医疗创新领域，启明创投是中国最早全面进入这一领域进行创业投资的团队之一。过去二十余年间，启明创投医疗创新团队累计投资了近200家企业，目前专注于创新药、创新器械、和AI医疗应用等。启明创投在该领域的深耕，不仅推动了中国医疗健康产业的创新发展，也为全球病患带来了切实的临床价值。

两大板块之间相互赋能。启明创投在医疗创新领域积累的产业认知，为AI医疗应用的投资提供了独特的洞察力；而科技板块的前沿技术判断，同样赋能医疗团队识别具备颠覆性潜力的技术驱动型企业。这种跨板块的协同能力，是启明创投的系统性优势。

在Midas List这一全球最高级别的投资人榜单上，从科技到医疗创新，再到人工智能，启明创投的投资人在不同年份、不同领域持续获得全球认可，底层是启明创投成立近二十年来形成的系统能力：聚焦两大核心板块的长期定力，“快半步”的系统化布局，以及覆盖早期到成长期的全链条专业能力。

无论是科技还是医疗创新领域，启明创投都在市场共识形成前多年便开始系统布局，以长期主义姿态陪伴企业成长，最终在退出端迎来丰收。

启明创投创始主管合伙人邝子平曾这样判断：“未来二十年，投资AI是中国投资最大的确定性。”如今，这一判断也正在被团队在募投管退上的正向循环所验证。

Qiming Venture Partners Managing Partner Alex Zhou Named to 2026 Forbes Midas List

Forbes has released its 2026 Midas List, the definitive ranking of the world’s top venture capital investors. Alex Zhou, Managing Partner at Qiming Venture Partners, debuts at No. 80, recognizing his track record as a leading China-based investor focused on technology and artificial intelligence.

Known as the "Oscars of venture capital," the Midas List is the most prestigious benchmark in global venture capital. The 2026 list marks its 25th anniversary, with intensified competition across the industry. Surging valuations for frontier companies including SpaceX, OpenAI and Anthropic have brought 25 new entrants to this year’s ranking.

Alex Zhou joined Qiming Venture Partners in 2014 and was promoted to Managing Partner in May 2024. He brings over 20 years of combined operational, entrepreneurial and investment experience, with a long-term focus on frontier technologies. He is one of the most active investors backing transformative AI and robotics startups globally.

Alex Zhou has delivered strong exit momentum in 2026. In the first five months of the year, four of his portfolio companies — Biren Technology, Zhipu AI, Axera Semiconductor and Viewtrix Technology — have completed public listings.

Alex Zhou adopts a pragmatic “half-step ahead” investment approach for tech and AI. Within his core areas of expertise, he identifies early industry inflection points and builds positions ahead of mainstream trends, avoiding speculative market hype. This forward-looking strategy has enabled him to capture outsized returns amid major technological paradigm shifts.

In late 2019, when China’s domestic GPU ecosystem remained immature and AI computing power was yet to gain widespread market recognition, Alex Zhou invested in Biren Technology at its founding. He led the company’s seed round and continued to support subsequent financings, helping the firm grow into the first Hong Kong-listed GPU company.

Alex Zhou made another early, high-impact bet on foundational AI in early 2022. At the time, large language models were still an emerging technology, and few investors recognized their commercial potential. His investment in Zhipu AI supported the development of the company’s first-generation GLM model, laying the foundation for its core technology development.

Alex Zhou’s early-stage focus also extends to embodied intelligence. He backed UBTECH Robotics eleven years ago and, in the current wave of embodied AI development, has led investments in a new batch of full-stack robotics companies integrating models and hardware, including TARS, Dexmal, GalaxyBot and ACE Robotics.

Founded in 2006, Qiming Venture Partners manages 11 USD funds and seven RMB funds, with $9.5 billion in assets under management. The firm focuses on two core pillars — technology and healthcare — forming a stable dual-driven investment strategy.

Qiming Venture Partners has maintained a long-term AI investment layout for over a decade. Starting with deep learning-focused investments in 2013, the firm has deployed more than RMB 12 billion into over 100 AI projects across the full industrial value chain, establishing itself as one of the most active and influential AI investors in China and Asia. The firm’s investment roadmap follows technological evolution across LLMs, multimodal AI and embodied intelligence, rather than short-term market trends.

In healthcare, Qiming Venture Partners is one of China’s earliest institutional investors dedicated to the sector. Over the past two decades, its healthcare team has invested in nearly 200 companies covering innovative pharmaceuticals, innovative medical devices, AI healthcare applications and other related areas. Its continuous investment has driven innovation in China’s life sciences industry and delivered practical clinical value globally.

Qiming Venture Partners’ technology and healthcare practices complement and empower one another. The firm’s healthcare industry expertise supports its judgments on AI+ healthcare applications opportunities, while its frontier tech insights help identify disruptive technology-driven healthcare startups. This cross-sector synergy forms Qiming Venture Partners’ key institutional advantage.

Qiming Venture Partners' recurring recognition on the Midas List across technology, healthcare and AI reflects its long-built institutional capabilities: consistent focus on core sectors, proactive early deployment, and full-cycle investment expertise covering early to growth-stage companies.

Across both core verticals, Qiming Venture Partners' executes systematic layout years before market consensus emerges, partnering with founders for long-term growth and achieving steady exit results.

“For the next two decades, AI will stand as the most certain investment opportunity in China’s venture landscape,” said Duane Kuang, Founding Managing Partner of Qiming Venture Partners. The firm’s healthy cycle of fundraising, investment, portfolio management and exits continues to validate this long-term judgment.

（转自：启明创投）